Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines his research highlights from the 2020 ASCO GU meeting. Dr Sonpavde discusses the combination of enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma as well as the ATLAS trial (NCT03397394). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.